|Biological half-life||7-27 hours|
|Chemical and physical data|
|Molar mass||311.42 g/mol|
|3D model (Jmol)|
Femoxetine (INN) (tentative brand name Malexil; developmental code name FG-4963) is a drug related to paroxetine that was being developed as an antidepressant by Danish pharmaceutical company Ferrosan in 1975 before acquisition by Novo Nordisk. It acts as a selective serotonin reuptake inhibitor (SSRI). Development was halted to focus attention on paroxetine instead, given femoxetine's inability to be administered as a daily pill.
Both femoxetine and paroxetine were invented in the 1970s by Jorgen Buus-Lassen (Jørgen Anders Christensen name on the patents though). Jorgen Buus-Lassen's name is on the pharmacology paper though.
After Ferrosan's acquisition, femoxetine died from neglect.
- U.S. Patent 3,912,743
- U.S. Patent 4,007,196
- Lassen, Jørgen Buus; Petersen, Erling; Kjellberg, Bengt; Olsson, Sven O. (1975). "Comparative studies of a new 5HT-uptake inhibitor and some tricyclic thymoleptics". European Journal of Pharmacology. 32 (1): 108–115. ISSN 0014-2999. doi:10.1016/0014-2999(75)90329-5.
- Healy, David (2004). Let them eat Prozac : the unhealthy relationship between the pharmaceutical industry and depression. New York, NY: New York Univ. Press. pp. 26–27. ISBN 9780814736692.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|